All In Biotech

Drug Trial Radar · NCT00158574

Kilimanjaro IPTi Drug Options Trial

Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs

Last checked: Nov 19, 2026Latest source record: Jan 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,419 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,419

Actual

Start

Jan 2005

Primary completion

Apr 2008

Study completion Jun 2008

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Copenhagen; National Institute for Medical Research, Tanzania; Kilimanjaro Christian Medical Centre, Tanzania
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 2 months, up to 24 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Malaria and anaemia are major causes of morbidity and mortality in children in sub-Saharan Africa. Administration of three courses of sulfadoxine/pyrimethamine (SP) as intermittent preventive treatment (IPTi) to infants when they receive EPI vaccines reduced the incidence of malaria and anaemia in infants in an area with low SP resistance, low transmission pressure and high bednet use. However, it is not clear whether this observation can be generalised to areas with high transmission and high SP resistance. The mechanism of the protective effect of IPTi is unclear. There is an urgent need to identify other anti-malarial drugs that could be used for IPTi instead of SP. This study objectives are: 1. Identification of a drug that could be used safely and effectively for IPTi instead of SP in areas, such as north eastern Tanzania, where there is a high level of resistance to SP and amodiaquine. 2. Determination of whether a short acting antimalarial drug (Lapdap) is as effective as a long acting drug (mefloquine) when used for IPTi. 3. Investigation of the effect of the intensity of transmission on the requirements for a long or short acting drug for IPTi. 4. Assessment of the effect of IPTi on the development of clinical immunity in children in low and high transmission areas. A randomised trial with four treatment regimes is proposed which will be conducted in two different transmission settings. The four treatment regimens are as follows: (1) placebo; (2) mefloquine; (3) Lapdap; (4) SP. All medications will be given at the time of immunisation with DPT/polio 2, DPT/polio 3, and measles vaccines. The study will involve 1280 infants in a high endemic area and 2440 infants in a low endemic area, in Tanzania.The primary outcome is the incidence of clinical malaria.

Conditions

  • Malaria

Interventions

  • sulphadoxine-pyrimethamineDrug

  • mefloquineDrug

  • Chlorproguanil-dapsoneDrug

  • PlaceboDrug

    Placebo

  • Sulphadoxine-pryrimethamineDrug

    IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg

  • IPTi mefloquineDrug

    IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg

  • Chlorproguanil dapsoneDrug

    IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Incidence of clinical malaria: [(history of fever during previous 2 days or axillary temperature >37.5ºC) + parasitaemia of any density + absence of any other obvious causes of fever] during the period of 3-11 months of ageTime frame: 3-11 months of age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ministry of Health, Korogwe and Same District MCH clinics

    Tanga, Tanga and Kilimanjaro, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.